Based on the observation in previous studies (Chen et al., 2019; Giribaldi et al., 2013; Liu et al., 2018), we hypothesized that RCN1 could be a promising prognostic marker or as a response predictor for targeted therapy in GBM. This evidence concerns the gene RCN1 and glioblastoma.